Yong-Liang Zhu

USPTO Granted Patents = 36 (Patent Applications = 21)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 14 (Patent Applications = 15)

Average Co-Inventor Count = 2.4

ph-index = 11

Forward Citations = 401(Granted Patents)

Company Filing History:

Elan Pharmaceuticals, Inc.

patents

Years Active: 2011-2025

Loading Chart...

36 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12403145 - Substituted quinazolines for inhibiting kinase activity (2025-09-02),

2. 12018002 - Certain chemical entities, compositions, and methods (2024-06-25),

3. 11865120 - Substituted quinazolines for inhibiting kinase activity (2024-01-09),

4. 11304957 - Substituted quinazolines for inhibiting kinase activity (2022-04-19),

5. 11208388 - Certain chemical entities, compositions, and methods (2021-12-28),

6. 10947201 - Certain chemical entities, compositions, and methods (2021-03-16),

7. 10759766 - Certain chemical entities, compositions, and methods (2020-09-01),

8. 10653701 - Substituted quinazolines for inhibiting kinase activity (2020-05-19),

9. 10590106 - Certain chemical entities, compositions, and methods (2020-03-17),

10. 10561652 - Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer (2020-02-18),

11. 10544106 - Certain chemical entities, compositions, and methods (2020-01-28),

12. 10457641 - Certain chemical entities, compositions, and methods (2019-10-29),

13. 10426760 - Compounds and methods for kinase modulation, and indications therefor (2019-10-01),

14. 10172868 - Substituted quinazolines for inhibiting kinase activity (2019-01-08),

15. 10137125 - Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer (2018-11-27),

Title: Yong-Liang Zhu: Innovator in Pharmaceutical Chemistry

Introduction

Yong-Liang Zhu, based in Fremont, CA, is a distinguished inventor in the field of pharmaceutical chemistry. With an impressive portfolio of 35 patents, he has made significant contributions to the development of therapeutic agents aimed at combating cancer. His work exemplifies the intersection of innovation and practical applications in the realm of drug development.

Latest Patents

Among Yong-Liang Zhu's latest patents are innovative chemical entities and compositions focusing on kinase inhibitors. These patents describe novel pharmaceutical compositions and methods for the treatment of cancer. His two notable patents, "Certain chemical entities, compositions, and methods” and "Substituted quinazolines for inhibiting kinase activity," specifically outline approaches that target kinase activity, which is pivotal in cancer progression.

Career Highlights

Throughout his career, Yong-Liang Zhu has been associated with prominent companies like Neupharma, Inc. and Plexxikon Inc., where he has played a critical role in advancing research and development in cancer therapeutics. His expertise in pharmaceutical chemistry has enabled him to contribute to significant projects and initiatives within these organizations.

Collaborations

Yong-Liang Zhu has collaborated with notable researchers in his field, including Xiangping Qian and Dean R Artis. These collaborations have driven forward innovative research, allowing for the sharing of knowledge and the cross-pollination of ideas, which are vital in the fast-evolving field of pharmaceutical sciences.

Conclusion

Yong-Liang Zhu's extensive number of patents and his dedication to advancing cancer treatment through innovative chemical solutions mark him as a leading figure in his domain. His work not only showcases significant advancements in pharmaceutical chemistry but also highlights the importance of collaboration and innovation in tackling complex health challenges.

This text is generated by artificial intelligence and may not be accurate.